Understanding spatial heterogeneity of drug resistant tuberculosis
Project Number7K01AI102944-04
Former Number5K01AI102944-03
Contact PI/Project LeaderJENKINS, HELEN E.
Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
DESCRIPTION (provided by applicant): This application is for a K01 Award for Dr. Helen Jenkins, a Research Fellow in the Global Health Equity Division at Brigham and Women's Hospital (BWH). Drug resistant strains of Mycobacterium tuberculosis (TB) threaten TB control. The detection and successful treatment of drug resistant TB (DR-TB) are compromised by the costly and time-consuming detection methods that are currently available in most settings. The severe under-estimation of this epidemic is a barrier to effective control. Undiagnosed DR-TB cases have poorer outcomes and may transmit disease for longer. Identifying hotspots of drug resistance is difficult when either access to or usage of drug susceptibility testing is limited, a in most settings. This project aims to develop methods for the spatial analysis of DR-TB data that account for geographic variation in diagnostic testing and allow identification of high DR-TB incidence. Datasets from two of the most concerning regions of the world
with regard to DR-TB, Eastern Europe and sub-Saharan Africa, will be used. The specific aims are: (A)
Describe and understand heterogeneity and clustering of DR-TB in an area with high levels of diagnostics, (B) Develop methods for estimating DR-TB burden in an area with geographic heterogeneity in diagnostic use, (C) Describe and understand heterogeneity in DR-TB burden accounting for substantial geographic variation in diagnostic testing, (D) Identify risk factors fo the development and acquisition of drug resistance during TB treatment. This work will provide a methodological framework for analyzing similar datasets in these regions. The proposed project can help identify the mechanisms by which DR-TB emerges thus facilitating identification of interventions that ensure more patients receive timely and appropriate treatment and limit spread of resistant forms of disease. Dr. Jenkins' mentors will be Dr. Marcello Pagano, PhD, Professor of Statistical Computing in the Department of Biostatistics, Harvard School of Public Health (HSPH) whose research focuses on
surveillance and statistical methods for infectious diseases and Dr. Ted Cohen, MD, MPH, DrPH, Assistant Professor of Epidemiology at HSPH and Associate Professor of Medicine at BWH who conducts research on TB epidemiology and DR-TB surveillance. Dr. Jenkins's advisory committee will include Dr. Marc Lipsitch, DPhil, Professor of Epidemiology at HSPH, Jeff Blossom, MSc, GIS expert at the Center for Geographic Analysis, Harvard University and Dr. Sonya Shin, MD, MPH, Associate Physician at BWH. Dr. Jenkins' training goals are (1) to become an expert in the analysis of spatial data and (2) obtain a solid understanding of the biology of infectious disease and she will take courses to achieve these. The research experience and training that Dr. Jenkins receives will provide her with the skills and preliminary data necessary to apply for R01 funding in the U.S. towards the end of the Award period. In the long-term, Dr. Jenkins aims to become an independent researcher developing and applying bio-statistical spatial methods in infectious disease epidemiology.
Public Health Relevance Statement
PUBLIC HEALTH RELEVANCE: Under-detection of drug-resistant tuberculosis (DR-TB) compromises the control of tuberculosis in areas where highly resistant forms of disease are emerging. The proposed research will develop methods to estimate DRTB incidence that account for spatial variation in drug susceptibility testing and thus facilitate the identificationof true DR-TB "hot-spots". In turn, this will allow for investigation of local drivers of DR-TB, infor the design of control interventions, and ultimately ensure that more patients receive appropriate treatment.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
604483045
UEI
FBYMGMHW4X95
Project Start Date
06-June-2013
Project End Date
31-May-2018
Budget Start Date
01-September-2015
Budget End Date
31-May-2016
Project Funding Information for 2015
Total Funding
$108,154
Direct Costs
$100,724
Indirect Costs
$7,430
Year
Funding IC
FY Total Cost by IC
2015
National Institute of Allergy and Infectious Diseases
$108,154
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7K01AI102944-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7K01AI102944-04
Patents
No Patents information available for 7K01AI102944-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7K01AI102944-04
Clinical Studies
No Clinical Studies information available for 7K01AI102944-04
News and More
Related News Releases
No news release information available for 7K01AI102944-04
History
No Historical information available for 7K01AI102944-04
Similar Projects
No Similar Projects information available for 7K01AI102944-04